Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Siena – page 11

225 clinical trials in Siena, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Siena at a glance
225
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

225 trials in Siena

Open in trial search

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib
  • Sponsor:Ipsen Innovation

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:BioNTech SE

Malignant melanoma

Not recruiting

A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Avian influenza

Not recruiting

Study of H5N8 influenza vaccine in adults previously vaccinated with H5N1/MF59 vaccine compared to those never vaccinated with H5 vaccine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Universiteit Antwerpen

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of CAL101 for Patients with Idiopathic Pulmonary Fibrosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:CAL101
  • Sponsor:Calluna Pharma AS

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18+ with Lung or Kidney Transplants at Risk of RSV Infections, Compared to Healthy Adults 50+

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Chronic myeloid leukaemia

Not recruiting

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Obesity

Not recruiting

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer+1

Not recruiting

Study of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:iOnctura SA

Glioblastoma

Not recruiting

Study on the Effectiveness of Optune with Temozolomide and Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Novocure GmbH

Relapsing-remitting multiple sclerosis

Not recruiting

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Siena

What the registry says about research in the country

01 Respiratory Research

Clinical investigations focusing on pulmonary conditions, including studies of treatments for idiopathic pulmonary fibrosis and chronic rhinosinusitis. Research also includes innovative approaches for respiratory syncytial virus prevention in older adults.

  • Pulmonary Fibrosis Treatment Studies
  • Chronic Rhinosinusitis Management
  • RSV Vaccine Development
02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced therapies for lung cancer, Merkel cell carcinoma, and hematological malignancies.

  • Non-Small Cell Lung Cancer Treatments
  • Leukemia Therapies
  • Novel Cancer Immunotherapies
03 Metabolic & Cardiovascular Research

Innovative trials examining treatments for heart failure prevention and obesity management, with focus on new therapeutic combinations and cardiovascular safety assessments.

  • Heart Failure Prevention
  • Obesity Management
  • Cardiovascular Risk Reduction
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.